Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 141 matching trials from the live ClinicalTrials.gov search.
Conditions
Retinitis Pigmentosa
Interventions
DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts • Minneapolis, Minnesota
Conditions
Retinitis Pigmentosa
Interventions
Low Dose NT-501, High Dose NT-501
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
18 Years to 68 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more
Conditions
X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-RPGR
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
8 Years to 50 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Jacksonville, Florida • Boston, Massachusetts • Cincinnati, Ohio + 3 more
Conditions
X-Linked Retinitis Pigmentosa
Interventions
Other: Assessments
Other
Lead sponsor
NightstaRx Ltd, a Biogen Company
Other
Eligibility
7 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-hRPGRco, Control
Biological · Drug
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years to 50 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 15 more
Conditions
Retinitis Pigmentosa
Interventions
Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
5 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
La Jolla, California • Stanford, California • Atlanta, Georgia + 3 more
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2
Interventions
RNA antisense oligonucleotide for intravitreal injection
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more
Available No phase listed Expanded access

Expanded Access Program for RP in Adults

NCT06574997
Conditions
Retinitis Pigmentosa
Interventions
OCU400
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years to 99 Years
U.S. locations
5
States / cities
Phoenix, Arizona • Deerfield Beach, Florida • Erie, Pennsylvania + 2 more
Conditions
Retinitis Pigmentosa
Interventions
Lutein (10 or 30 mg/day) capsules
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
Not listed
Timeline
2001 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting No phase listed Observational

ARPKD Database Study

NCT01401998
Conditions
Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease, Joubert Syndrome, Bardet Biedl Syndrome, Meckel-Gruber Syndrome, Congenital Hepatic Fibrosis, Caroli Syndrome, Oro-Facial-Digital Syndrome Type I, Nephronophthisis, Glomerulocystic Kidney Disease
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2030
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 3 more
Active, not recruiting Phase 1Phase 2 Interventional

Promising ROd-cone DYstrophy Gene therapY

NCT05748873
Conditions
Retinitis Pigmentosa
Interventions
SPVN06
Drug
Lead sponsor
SparingVision
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Portland, Oregon + 2 more
Conditions
Retinitis Pigmentosa
Interventions
Transcorneal Electrical Stimulation using Okustim device
Device
Lead sponsor
Wills Eye
Other
Eligibility
22 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting Phase 3 Interventional

Oral N-acetylcysteine for Retinitis Pigmentosa

NCT05537220
Conditions
Retinitis Pigmentosa
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 21 more
Completed Phase 1 Interventional

The FIGHT-RP1 Study

NCT03063021
Conditions
Retinitis Pigmentosa
Interventions
N-Acetyl Cysteine (NAC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Retinitis Pigmentosa, Eye Diseases
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
13
States / cities
San Francisco, California • Denver, Colorado • Gainesville, Florida + 10 more
Conditions
Retinitis Pigmentosa
Interventions
CAREN system training
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Retinitis Pigmentosa
Interventions
Argus 16 Retinal Stimulation System
Device
Lead sponsor
Second Sight Medical Products
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Retinitis Pigmentosa
Interventions
Anterior Chamber (AC) tap
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
X-Linked Retinitis Pigmentosa
Interventions
Genetic: AAV5-hRKp.RPGR Intermediate Dose, Genetic: AAV5-hRKp.RPGR Low Dose
Biological
Lead sponsor
MeiraGTx Ocular UK Ltd
Industry
Eligibility
3 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
Recruiting No phase listed Observational Accepts healthy volunteers

High Resolution Retinal Imaging

NCT01866371
Conditions
Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia, Geographic Atrophy
Interventions
Retinal imaging
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
7 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
X-Linked Retinitis Pigmentosa
Interventions
4D-125 IVT Injection, Observational
Biological · Other
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
12 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
8
States / cities
Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 5 more
Conditions
Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa, Hereditary Macular Degeneration
Interventions
CD34+ bone marrow stem cells intravitreal
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Sacramento, California